Drug
GSK3923868 clinical trials
Also written GSK3923868.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GSK3923868 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy ParticipantsCompletedPhase 1GlaxoSmithKlineNCT06597500Written as GSK3923868
- Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European AncestryCompletedPhase 1GlaxoSmithKlineNCT06577597Written as GSK3923868
- Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 1GlaxoSmithKlineNCT05677347Written as GSK3923868
- Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild AsthmaCompletedPhase 1GlaxoSmithKlineNCT05398198Written as GSK3923868
- Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable AsthmaticsCompletedPhase 1GlaxoSmithKlineNCT04585009Written as GSK3923868